BioNTech (NASDAQ:BNTX) pushed back on speculation Thursday that Pfizer (NYSE:PFE) may be preparing to unload its stake in the company, emphasizing that the two firms’ long-running alliance remains solid.
A spokesperson for the German biotech firm said, “We continue to have a close and strong collaboration,” adding that BioNTech would not comment on any equity-related decisions made by Pfizer.
The clarification follows market chatter suggesting Pfizer might consider selling its holding in BioNTech, its partner in developing one of the world’s most widely administered COVID-19 vaccines.